CSPG4 and obstructive sleep apnea syndrome: Preliminary in vitro studies have signaled the potential efficacy of CSPG4 immune-targeting, with anti-CSPG4 antibodies that impair OSA cell proliferation, migration and sphere formation, when used alone and in combination with DOXO treatment [165].